SCHEMBL22532348

SCHEMBL22532348

COc1cc(OC)cc(-c2cc3cnc(NCCCN4CCN(CCCC(=O)O)CC4)nc3nc2NC(=O)NC(C)(C)C)c1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 20/20 0.87
▸ FGFR2 P21802 17/20 0.87
▸ FGFR4 P22455 17/20 0.87
▸ FGFR3 P22607 17/20 0.87
▸ KDR P35968 12/20 0.87
▸ FLT1 P17948 11/20 0.87
▸ FLT4 P35916 11/20 0.87
▸ SRC P12931 3/20 0.68
▸ GLA P06280 1/20 0.68
▸ CSK P41240 1/20 0.68
▸ KMT2A Q03164 1/20 0.68
▸ ATM Q13315 1/20 0.68
▸ EGFR P00533 4/20 0.63
▸ PRKD3 O94806 1/20 0.62
▸ PRKCG P05129 1/20 0.62
▸ PRKCB P05771 1/20 0.62
▸ PRKCA P17252 1/20 0.62
▸ PRKCH P24723 1/20 0.62
▸ PRKCI P41743 1/20 0.62
▸ PRKCE Q02156 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388263 1.00 FGFR1 (0.87) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL29391039 0.94 FGFR1 (0.87) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22532398 0.94 FGFR1 (0.87) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL24490292 0.93 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22532573 0.92 FGFR1 (0.84) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL29388286 0.92 FGFR1 (0.84) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL19601461 0.92 FGFR1 (0.88) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL22532606 0.90 FGFR1 (0.86) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL29391222 0.90 FGFR1 (0.86) FGFR1FGFR2FGFR4FGFR3KDR
Hydrochloric Acid SCHEMBL22531887 0.90 FGFR1 (0.84) FGFR1FGFR2FGFR4FGFR3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220175722-A1 DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-06-09 — — US disclosed
US-20220175722-A1 DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-06-09 — — US disclosed
EP-3952863-A1 DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) Dana-Farber Cancer Institute, Inc. (US) 2022-02-16 — — EP disclosed
WO-2020210451-A1 DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175722-A1 DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FGFR2, FGF2, FGFR1 FGFR1 3/4885FGFR2 1/4885FGFR4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback